Abstracts

WEIGHT AND LIPID CHANGES IN PHASE 3 CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING TRIALS

Weight gain and metabolic alterations have been reported with integrase strand transfer inhibitor (INSTI)-based antiretroviral (ARV) regimens. Long-acting (LA) cabotegravir (CAB), an INSTI, and rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor, constitute a highly effective 2-drug regimen administered intramuscularly monthly or every 2 months for the maintenance of virologic suppression. Weight and lipid changes over…

ASSESSMENT OF OBESITY AND METABOLIC PROFILE BY INTEGRASE INHIBITOR USE IN REPRIEVE

Among people with HIV (PWH), use of integrase inhibitor (INSTI)-based antiretroviral treatment (ART) has been associated with weight gain, but the health consequences of this weight gain remain unknown. Leveraging baseline data from a large, international cohort of ART-treated PWH eligible for primary cardiovascular disease (CVD) prevention, we investigated the association of INSTI vs. non-INSTI-based…

ASSOCIATION BETWEEN NEWER ANTIRETROVIRALS AND INCREASE IN BODY MASS INDEX IN RESPOND

Weight gain has been related to use of tenofovir alafenamide (TAF) and integrase inhibitor (INSTIs), particularly dolutegravir (DTG). However, the independent effects of individual contemporary antiretrovirals (ARVs) on weight gain are not fully understood. We investigated associations between pre-specified clinically significant increase (>7%) and extreme increase (>30%) in body mass index (BMI) and contemporary ARV…

OBESITY IS HIGHLY PREVALENT IN PEOPLE OF AFRICAN ANCESTRY LIVING WITH HIV IN THE UK

Obesity is a global public health emergency, and people of African ancestry are disproportionally affected. Data on obesity, and associated health issues such as diabetes mellitus (DM) and hypertension (HPT), in African populations with HIV are relatively sparse. We determined the prevalence of, and factors associated with, obesity in the GEN-AFRICA cohort. Participants were recruited…

IN VITRO MODEL TO ASSESS ANTIRETROVIRAL THERAPY ON ADIPOCYTE BIOLOGY

Antiretroviral therapies (ART) have diverse effects on adipose tissue biology, clinically observed through changes in weight and fat distribution with ART initiation or switch. These effects likely occur in a fat depot-specific manner, however the mechanisms remain poorly understood. Our objective was to develop an in-vitro model which allows in-depth examination of the cellular effects…